prostate-report.org

Fosamax Drug Can Slow Bone Loss in Prostate Cancer Patients

Men receiving hormone-deprivation therapy for advanced but localized prostate cancer can develop bone loss as a side effect of the treatment.

But a new study finds that bone-strengthening drugs such as Fosamax (generic name alendronate) can help prevent that damage.

Having earlier found that alendronate successfully prevents bone loss for patients on hormone-depletion therapy after just one year, the current follow-up reveals that two years of the drug affords men even greater protection. [ full medical news ]